Rutgers University’s Resilient, Innovative Year Confronting COVID-19

The last year, which has been unlike any other in Rutgers’ 254-year history, has centered on keeping the Rutgers community safe, providing top-notch health care, developing the first saliva test for the coronavirus and helping society cope with the biggest global public health crisis since the 1918 influenza pandemic.

Read more

Science Snapshots: COVID-19, power outages, Alzheimer’s disease, and optical antennas

March Science Snapshots from Berkeley Lab

Read more

Sewage-Handling Robots Help Predict COVID-19 Outbreaks in San Diego

UC San Diego School of Medicine researchers develop an automated process to test city sewage for SARS-CoV-2, allowing them to forecast the region’s COVID-19 caseload one to two weeks ahead of clinical diagnostic reports.

Read more

More than 1,000 SARS-CoV-2 Coronavirus Protein 3D Structures Available

New Brunswick, N.J. (March 3, 2021) – The 3D structures of more than 1,000 SARS-CoV-2 coronavirus proteins are freely available

Read more

RGF® Environmental Group Releases Industry’s First Test Evaluating Aerosolized SARS-CoV-2 Viral Reductions Directly in the Air: PHI-PKG14 PHI-CELL® Proven to Inactivate 99.96% of Airborne SARS-CoV-2 within Simulated Air-Conditioned Space

RGF® Environmental Group, Inc., a leading environmental design and manufacturing company, has released the results of a third-party test that proves the PHI-PKG14 PHI-CELL® product with Photohydroionization® technology inactivates greater than 99.96% of airborne SARS-CoV-2 virus.

Read more

Repurposed Arthritis Drug Did Not Significantly Improve Severe COVID-19 Pneumonia

A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo.

Read more

Balanced T cell response key to avoiding COVID-19 symptoms, study suggests

By analyzing blood samples from individuals infected with SARS-CoV-2, researchers in Singapore have begun to unpack the different responses by the body’s T cells that determine whether or not an individual develops COVID-19. The study, published today in the Journal of Experimental Medicine (JEM), suggests that clearing the virus without developing symptoms requires T cells to mount an efficient immune response that produces a careful balance of pro- and anti-inflammatory molecules.

Read more

NIH Awards UC San Diego $33 Million for Five COVID-19 Diagnostic Projects

UC San Diego was awarded five COVID-19 Rapid Acceleration of Diagnostics (RADx) projects by the National Institutes of Health totaling nearly $33 million, which will fund efforts that range from managing a large data center to expanding testing in disadvantaged communities.

Read more

Human Lung and Brain Organoids Respond Differently to SARS-CoV-2 Infection in Lab Tests

UC San Diego School of Medicine researchers are using stem cell-derived organoids to study how SARS-CoV-2 interacts with various organ systems. Their findings may help explain the wide variety in COVID-19 symptoms and aid the search for therapies.

Read more

Genetics May Play Role in Determining Immunity to COVID-19

UC San Diego researchers report that individual immune response to SARS-CoV-2 may be limited by a set of variable genes that code for cell surface proteins essential for the adaptive immune system. The finding may help explain why COVID-19 immunity varies by individual.

Read more